9 research outputs found
Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor β on mRNA stability and translatability
Estrogen signaling is mediated by estrogen receptors (ERs), ERα and ERβ. Aberrant
estrogen signaling is involved in breast cancer development. ERα is one of the key
biomarkers for diagnosis and treatment of breast cancer. Unlike ERα, ERβ is still not
introduced as a marker for diagnosis and established as a target of therapy. Numerous
studies suggest antiproliferative effects of ERβ, however its role remains to be fully
explored. Albeit important, ERα is not a perfect marker, and some aspects of ERα
function are still unclear. This thesis aims to characterize distinct molecular facets of
ER action relevant for breast cancer and provide valuable information for ER-based
diagnosis and treatment design.
In PAPER I, we analyzed the functionality of two common single
nucleotide polymorphisms in the 3’ untranslated regions of ERβ, rs4986938 and
rs928554, which have been extensively investigated for association with various
diseases. A significant difference in allelic expression was observed for rs4986938 in
breast tumor samples from heterozygous individuals. However, no difference in mRNA
stability or translatability between the alleles was observed.
In PAPER II, we provided a more comprehensive understanding of ERβ
function independent of ERα. A global gene expression analysis in a HEK293/ERβ cell
model identified a set of ERβ-regulated genes. Gene Ontology (GO) analysis showed
that they are involved in cell-cell signaling, morphogenesis and cell proliferation.
Moreover, ERβ expression resulted in a significant decrease in cell proliferation.
In PAPER III, using the human breast cancer MCF-7/ERβ cell model,
we demonstrated, for the first time, the binding of ERα/β heterodimers to various
DNA-binding regions in intact chromatin.
In PAPER IV, we investigated a potential cross-talk between estrogen
signaling and DNA methylation by identifying their common target genes in MCF-7
cells. Gene expression profiling identified around 150 genes regulated by both 17β-
estradiol (E2) and a hypomethylating agent 5-aza-2’-deoxycytidine. Based on GO
analysis, CpG island prediction analysis and previously reported ER binding regions,
we selected six genes for further analysis. We identified BTG3 and FHL2 as direct
target genes of both pathways. However, our data did not support a direct molecular
interplay of mediators of estrogen and epigenetic signaling at promoters of regulated
genes.
In PAPER V, we further explored the interactions between estrogen
signaling and DNA methylation, with focus on DNA methyltransferases (DNMT1,
DNMT3a and DNMT3b). E2, via ERα, up-regulated DNMT1 and down-regulated
DNMT3a and DNMT3b mRNA expression. Furthermore, DNMT3b interacted with
ERα. siRNA-mediated DNMT3b depletion increased the expression of two genes,
CDKN1A and FHL2. We proposed that the molecular mechanism underlying
regulation of FHL2 and CDKN1A gene expression involves interplay of DNMT3b and
ERα.
In conclusion, the studies presented in this thesis contribute to the knowledge of ERβ
function, and give additional insight into the cross-talk mechanisms underlying ERα
signaling with ERβ and with DNA methylation pathways
Assembly of Inflammation-Related Genes for Pathway-Focused Genetic Analysis
Recent identifications of associations between novel variants in inflammation-related genes and several common diseases emphasize the need for systematic evaluations of these genes in disease susceptibility. Considering that many genes are involved in the complex inflammation responses and many genetic variants in these genes have the potential to alter the functions and expression of these genes, we assembled a list of key inflammation-related genes to facilitate the identification of genetic associations of diseases with an inflammation-related etiology. We first reviewed various phases of inflammation responses, including the development of immune cells, sensing of danger, influx of cells to sites of insult, activation and functional responses of immune and non-immune cells, and resolution of the immune response. Assisted by the Ingenuity Pathway Analysis, we then identified 17 functional sub-pathways that are involved in one or multiple phases. This organization would greatly increase the chance of detecting gene-gene interactions by hierarchical clustering of genes with their functional closeness in a pathway. Finally, as an example application, we have developed tagging single nucleotide polymorphism (tSNP) arrays for populations of European and African descent to capture all the common variants of these key inflammation-related genes. Assays of these tSNPs have been designed and assembled into two Affymetrix ParAllele customized chips, one each for European (12,011 SNPs) and African (21,542 SNPs) populations. These tSNPs have greater coverage for these inflammation-related genes compared to the existing genome-wide arrays, particularly in the African population. These tSNP arrays can facilitate systematic evaluation of inflammation pathways in disease susceptibility. For additional applications, other genotyping platforms could also be employed. For existing genome-wide association data, this list of key inflammation-related genes and associated subpathways can facilitate comprehensive inflammation pathway- focused association analyses
Framtidsfrågor Restaureringskonst 2016-2017 Kungl Konsthögskolan
Restaureringskonst vid Kungl Konsthögskolan i Stockholm har läsåret 2016-2017 haft temat Framtidsfrågor. Utöver professionskunskap och teori har fronten och framtidsfrågor inom ämnet studerats. Publikationen visar en del av årets arbete i form av artiklar. Praktisk träning i dokumentation och värdering avspeglas liksom gemensamma studieresor, föreläsningar och milstolpar inom restaurering. Framtidsfrågor har inga enkla svar med för att kunskapsuppbyggnaden ska ligga i fronten är Restaureringskonst en aktiv deltagare i diskussionen
Development and Psychometric Evaluation of the Hypoglycemia Perspectives Questionnaire in Patients with Type 2 Diabetes Mellitus
Expression of Phosphorylated cAMP Response Element Binding Protein (p-CREB) in Bladder Afferent Pathways in VIP−/− Mice with Cyclophosphamide (CYP)-Induced Cystitis
Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations.
BACKGROUND: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. OBJECTIVES: To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI). DATA SOURCES: We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches. REVIEW METHODS: The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes. RESULTS: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally. LIMITATIONS: Most of the trials included participants with Alzheimer's disease, so recommendations may not apply to other types of dementia. We did not conduct economic analyses. The PPI consultation was limited to members of the Alzheimer's Society Research Network. CONCLUSIONS: Cognitive outcomes and biological markers form the core outcome set for future disease modification trials, measured by the MMSE or ADAS-Cog, and structural MRI in a subset of participants. FUTURE WORK: We envisage that the core set may be superseded in the future, particularly for other types of dementia. There is a need to develop an algorithm to compare scores on the MMSE and ADAS-Cog. STUDY REGISTRATION: The project was registered with Core Outcome Measures in Effectiveness Trials [ www.comet-initiative.org/studies/details/819?result=true (accessed 7 April 2016)]. The systematic review protocol is registered as PROSPERO CRD42015027346. FUNDING: The National Institute for Health Research Health Technology Assessment programme